New York City, NY -- (SBWIRE) -- 01/03/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Tesco PLC (ADR) (OTCMKTS:TSCDY), Cannabis Science Inc (OTCMKTS:CBIS), Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT), FANNIE MAE PFD S (OTCBB:FNMAS)
Tesco PLC (ADR) (OTCMKTS:TSCDY) declined -2.55%, trading on 436,546 shares, to end the trade at $16.41. If we look at its trading history of the past 52 weeks, the share price suffered a low of $15.10 and was moved to the maximum level of $18.51. The stock changed hands in a range of $16.28 to $16.44, bringing its market capitalization to about $44.21 billion. Tesco PLC is an international retailer. The activity of the Company is retailing and associated activities in the United Kingdom, the People’s Republic of China, the Czech Republic, Hungary, the Republic of Ireland, India, Malaysia, Poland, Slovakia, South Korea, Thailand, Turkey and the United States.
Will TSCDY Get Buyers Even After The Recent Rally? Find Out Here
Cannabis Science Inc (OTCMKTS:CBIS) added 55.15%, to complete the trading session at $0.0799, with a total volume of 88.38 million shares. The stock, on average, trades on a volume of 4.86 million shares. In the past 52 weeks, the share price has not declined below $0.03 and above $0.12. It floated in a range of $0.06 to $0.09 during the last trading session, with a beta value of 10.33. Its market capitalization now moved to about $60.83 million.
What was the Moving Force behind CBIS on Bullish Run? Read This Research Report
Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT) recorded a gain of 12.86% and was in a range of $2.45-$2.73 before closing at $2.72. The share price hit its 52-week low of $0.55 and $2.73 was the best price. The stock completed the day with a total volume of 2.38 million shares, versus an average volume of 1.49 million shares. Provectus Pharmaceuticals, Inc. is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10.
For How Long FNMAS will fight for Profitability? Read This Trend Analysis report
FANNIE MAE PFD S (OTCBB:FNMAS) declined -1.14% yesterday, bringing its market capitalization around $2.45 billion. The total number of shares that changed hands during the session was 638,747 shares, as compared to average trading volume of 873,324 shares. The share price, after opening at $8.65, made a high of $8.65 and hovered above $8.50 to end the day at $8.65.
Will FNMAS Bounce Back After yesterday’s Sharp Sell off? Find Out Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)